Baseline testosterone levels in men with clinically localized high-risk prostate cancer treated with radical prostatectomy with or without neoadjuvant chemohormonal therapy (Alliance)
- Citation:
- J Urol vol 206 (2) 319-324
- Year:
- 2021
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- Yes
- Book Volume:
- 10
- Parents:
- None
- Children:
- None
- Pharmas:
- Sanofi
- Grants:
- U10CA180821, U10CA180882, UG1CA233180, UG1CA233191, UG1CA233290
- Corr. Author:
- Authors:
- James A. Eastham Glenn Heller David W. Hillman Olwen M. Hahn J. Kellogg Parsons James L. Mohler Eric J. Small Michael Morris
- Networks:
- CA249, CA824, LAPS-IL057, LAPS-NY016, LAPS-NY158
- Study
- CALGB-90203
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords:
- testosterone, radical prostatectomy, prostatic neoplasms, neoadjuvant therapy